99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses

Circulation: Cardiovascular Imaging

Volumn 6, Issue 2, 2013, Pages 195-201

  Bokhari, Sabahat ^a   Castaño, Adam ^a   Pozniakoff, Ted ^a   Deslisle, Susan ^a   Latif, Farhana ^a   Maurer, Mathew S ^a  

^a Columbia College of Physicians and Surgeons ^*  (United States)

Author keywords

99mTc PYP scintigraphy; AL amyloid; ATTR transthyretin cardiomyopathy; Technetium

Indexed keywords

PREALBUMIN; PYROPHOSPHATE TECHNETIUM TC 99M; TRACER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

AMYLOIDOSIS; AREA UNDER THE CURVE; ARTICLE; CARDIAC IMAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RETENTION; FAMILIAL DISEASE; FEMALE; HEART AMYLOIDOSIS; HEART SCINTISCANNING; HUMAN; HUMAN TISSUE; MALE; MEDICAL DEVICE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION STUDY; AGED; CARDIOMYOPATHY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FAMILIAL AMYLOID POLYNEUROPATHY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SCINTISCANNING; STATISTICAL MODEL;

AGED; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHENOTYPE; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M PYROPHOSPHATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

MLCS; MLOWN;

EID: 84877325205     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.112.000132     Document Type: Article

References (37)

1. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60:765-774.
2. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203-1212.
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160-184.
4. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a lateonset disease of genetic etiology. Am J Hum Genet. 1990;47:127-136.
5. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466-473
6. Mirzoyev SA, Edwards WD, Mohammed SF, Donovan JL, Roger VL, Grogan DR, Redfield MM. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation. 2010;122:A17926.
7. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52:347-361.
8. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786-1791.
9. Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, Nadasdy T. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol. 2011;35:1685-1690.
10. Chee CE, Lacy MQ, Dogan A, Zeldenrust SR, Gertz MA. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk. 2010;10:177-180.
11. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957-4959.
12. 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076-1084.
13. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4:659-670.
14. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398-408.
15. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235:479-485.
16. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsyproven cardiac involvement. Am J Cardiol. 2005;95:535-537.
17. Chen W, Dilsizian V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep. 2012;14:226-233.
18. Janssen S, Piers DA, van Rijswijk MH, Meijer S, Mandema E. Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med. 1990;16:663-670.
19. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38:284-293.
20. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet. 1988;1:1413-1418.
21. Nielsen EH, Sørensen IJ, Vilsgaard K, Andersen O, Svehag SE. Calcium-enhanced aggregation of serum amyloid P component and its inhibition by the ligands heparin and heparan sulphate. An electron microscopic and immunoelectrophoretic study. APMIS. 1994;102:420-426.
22. Hamazaki H. Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's beta-amyloid peptide. J Biol Chem. 1995;270: 10392-10394.
23. Hongo M, Yamada H, Okubo S, Hirayama J, Fujii T, Kusama S, Ikeda S. Cardiac involvement in systemic amyloidosis: myocardial scintigraphic evaluation. J Cardiogr. 1985;15:163-180.
24. Ak I, Vardareli E, Erdinĉ O, Kasapoǧlu E, Ata N. Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin Nucl Med. 2000;25:826-827.
25. Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983;51:826-830.
26. Kula RW, Engel WK, Line BR. Scanning for soft-tissue amyloid. Lancet. 1977;1:92-93.
27. Eriksson P, Backman C, Bjerle P, Eriksson A, Holm S, Olofsson BO. Noninvasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J. 1984;52:321-326.
28. Karp K, Näslund U, Backman C, Eriksson P. Technetium-99m pyrophosphate single-photon emission computed tomography of the heart in familial amyloid polyneuropathy. Int J Cardiol. 1987;14:365-369.
29. Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med. 1987;147:1039-1044.
30. Castaño A, Bokhari S, Brannagan TH 3rd, Wynn J, Maurer MS. Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid. 2012;19: 41-46.
31. Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J. 1982;103(4 Pt 1):468-473.
32. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786-1791.
33. Yamamoto Y, Onoguchi M, Haramoto M, Kodani N, Komatsu A, Kitagaki H, Tanabe K. Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and (99m)Tc-PYP SPECT. Ann Nucl Med. 2012;26:634-643.
34. Willerson JT, Parkey RW, Bonte FJ, Meyer SL, Atkins JM, Stokley EM. Technetium stannous pyrophosphate myocardial scintigrams in patients with chest pain of varying etiology. Circulation. 1975;51: 1046-1052.
35. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008;51:1509-1510; author reply 1510.
36. Russo C GP, Maurer MS. Comparison of v122i and senile cardiac amyloidosis: differences in clinical features and outcomes. XIIIth International Symposium on Amyloidosis, OP 52. 2012:62 http://wencke4.housing.rug.nl/ documenten/medici/Internationale-Conferenties/SY-Amyloidosis%202012/documents/ ISAabstractbook2012.pdf. Accessed January 9, 2013.
37. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38:470-478.